Selected research
Industry Growth & Trends
Global Urotropin for Injection Industry Growth and Trends Forecast to 2032
Market perspective
The global Urotropin for Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Urotropin for Injection include Yantai Dongcheng North Pharmaceutical, Teva, Shanghai Tianwei Biopharmaceutical Co., Ltd., Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd., Qingdao Kangyuan Pharmaceutical, Ningbo Human Health Pharmaceutical Group, Ningbo Human Health Pharmaceutical, Merck and Maanshan Fengyuan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Urotropin for Injection market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Urotropin for Injection market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Urotropin for Injection market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Urotropin for Injection.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Urotropin for Injection market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Urotropin for Injection Market by Company
Yantai Dongcheng North Pharmaceutical
Teva
Shanghai Tianwei Biopharmaceutical Co., Ltd.
Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
Qingdao Kangyuan Pharmaceutical
Ningbo Human Health Pharmaceutical Group
Ningbo Human Health Pharmaceutical
Merck
Maanshan Fengyuan Pharmaceutical
Livzon Group
Ferring GmbH
Livzon
IBSA Group
GenSci
Gedeon Richter
Urotropin for Injection Segment by Type
75 Unit
150 Unit
Urotropin for Injection Segment by Application
Hospital
Clinic
Urotropin for Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urotropin for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urotropin for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urotropin for Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Urotropin for Injection manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Urotropin for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 75 Unit
- 150 Unit
Applications
- Hospital
- Clinic
Companies covered
- Yantai Dongcheng North Pharmaceutical
- Teva
- Shanghai Tianwei Biopharmaceutical Co., Ltd.
- Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
- Qingdao Kangyuan Pharmaceutical
- Ningbo Human Health Pharmaceutical Group
- Ningbo Human Health Pharmaceutical
- Merck
- Maanshan Fengyuan Pharmaceutical
- Livzon Group
- Ferring GmbH
- Livzon
- IBSA Group
- GenSci
- Gedeon Richter
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Urotropin for Injection Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Urotropin for Injection Sales Estimates and Forecasts (2021-2032)
- 1.3 Urotropin for Injection Market by Type
- 1.3.1 75 Unit
- 1.3.2 150 Unit
- 1.4 Global Urotropin for Injection Market Size by Type
- 1.4.1 Global Urotropin for Injection Market Size Overview by Type (2021-2032)
- 1.4.2 Global Urotropin for Injection Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Urotropin for Injection Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Urotropin for Injection Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Urotropin for Injection Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Urotropin for Injection Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Urotropin for Injection Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Urotropin for Injection Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Urotropin for Injection Industry Trends
- 2.2 Urotropin for Injection Industry Drivers
- 2.3 Urotropin for Injection Industry Opportunities and Challenges
- 2.4 Urotropin for Injection Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Urotropin for Injection Revenue (2021-2026)
- 3.2 Global Top Players by Urotropin for Injection Sales (2021-2026)
- 3.3 Global Top Players by Urotropin for Injection Price (2021-2026)
- 3.4 Global Urotropin for Injection Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Urotropin for Injection Major Company Production Sites & Headquarters
- 3.6 Global Urotropin for Injection Company, Product Type & Application
- 3.7 Global Urotropin for Injection Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Urotropin for Injection Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Urotropin for Injection Players Market Share by Revenue in 2025
- 3.8.3 2025 Urotropin for Injection Tier 1, Tier 2, and Tier 3
4 Urotropin for Injection Regional Status and Outlook
- 4.1 Global Urotropin for Injection Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Urotropin for Injection Historic Market Size by Region
- 4.2.1 Global Urotropin for Injection Sales in Volume by Region (2021-2026)
- 4.2.2 Global Urotropin for Injection Sales in Value by Region (2021-2026)
- 4.2.3 Global Urotropin for Injection Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Urotropin for Injection Forecasted Market Size by Region
- 4.3.1 Global Urotropin for Injection Sales in Volume by Region (2027-2032)
- 4.3.2 Global Urotropin for Injection Sales in Value by Region (2027-2032)
- 4.3.3 Global Urotropin for Injection Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Urotropin for Injection by Application
- 5.1 Urotropin for Injection Market by Application
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.2 Global Urotropin for Injection Market Size by Application
- 5.2.1 Global Urotropin for Injection Market Size Overview by Application (2021-2032)
- 5.2.2 Global Urotropin for Injection Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Urotropin for Injection Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Urotropin for Injection Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Urotropin for Injection Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Urotropin for Injection Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Urotropin for Injection Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Urotropin for Injection Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Yantai Dongcheng North Pharmaceutical
- 6.1.1 Yantai Dongcheng North Pharmaceutical Company Information
- 6.1.2 Yantai Dongcheng North Pharmaceutical Business Overview
- 6.1.3 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Product Portfolio
- 6.1.5 Yantai Dongcheng North Pharmaceutical Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Teva Urotropin for Injection Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Shanghai Tianwei Biopharmaceutical Co., Ltd.
- 6.3.1 Shanghai Tianwei Biopharmaceutical Co., Ltd. Company Information
- 6.3.2 Shanghai Tianwei Biopharmaceutical Co., Ltd. Business Overview
- 6.3.3 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio
- 6.3.5 Shanghai Tianwei Biopharmaceutical Co., Ltd. Recent Developments
- 6.4 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
- 6.4.1 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Company Information
- 6.4.2 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Business Overview
- 6.4.3 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio
- 6.4.5 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Recent Developments
- 6.5 Qingdao Kangyuan Pharmaceutical
- 6.5.1 Qingdao Kangyuan Pharmaceutical Company Information
- 6.5.2 Qingdao Kangyuan Pharmaceutical Business Overview
- 6.5.3 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Product Portfolio
- 6.5.5 Qingdao Kangyuan Pharmaceutical Recent Developments
- 6.6 Ningbo Human Health Pharmaceutical Group
- 6.6.1 Ningbo Human Health Pharmaceutical Group Company Information
- 6.6.2 Ningbo Human Health Pharmaceutical Group Business Overview
- 6.6.3 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Product Portfolio
- 6.6.5 Ningbo Human Health Pharmaceutical Group Recent Developments
- 6.7 Ningbo Human Health Pharmaceutical
- 6.7.1 Ningbo Human Health Pharmaceutical Company Information
- 6.7.2 Ningbo Human Health Pharmaceutical Business Overview
- 6.7.3 Ningbo Human Health Pharmaceutical Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Ningbo Human Health Pharmaceutical Urotropin for Injection Product Portfolio
- 6.7.5 Ningbo Human Health Pharmaceutical Recent Developments
- 6.8 Merck
- 6.8.1 Merck Company Information
- 6.8.2 Merck Business Overview
- 6.8.3 Merck Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Merck Urotropin for Injection Product Portfolio
- 6.8.5 Merck Recent Developments
- 6.9 Maanshan Fengyuan Pharmaceutical
- 6.9.1 Maanshan Fengyuan Pharmaceutical Company Information
- 6.9.2 Maanshan Fengyuan Pharmaceutical Business Overview
- 6.9.3 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Product Portfolio
- 6.9.5 Maanshan Fengyuan Pharmaceutical Recent Developments
- 6.10 Livzon Group
- 6.10.1 Livzon Group Company Information
- 6.10.2 Livzon Group Business Overview
- 6.10.3 Livzon Group Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Livzon Group Urotropin for Injection Product Portfolio
- 6.10.5 Livzon Group Recent Developments
- 6.11 Ferring GmbH
- 6.11.1 Ferring GmbH Company Information
- 6.11.2 Ferring GmbH Business Overview
- 6.11.3 Ferring GmbH Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 Ferring GmbH Urotropin for Injection Product Portfolio
- 6.11.5 Ferring GmbH Recent Developments
- 6.12 Livzon
- 6.12.1 Livzon Company Information
- 6.12.2 Livzon Business Overview
- 6.12.3 Livzon Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 Livzon Urotropin for Injection Product Portfolio
- 6.12.5 Livzon Recent Developments
- 6.13 IBSA Group
- 6.13.1 IBSA Group Company Information
- 6.13.2 IBSA Group Business Overview
- 6.13.3 IBSA Group Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.13.4 IBSA Group Urotropin for Injection Product Portfolio
- 6.13.5 IBSA Group Recent Developments
- 6.14 GenSci
- 6.14.1 GenSci Company Information
- 6.14.2 GenSci Business Overview
- 6.14.3 GenSci Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.14.4 GenSci Urotropin for Injection Product Portfolio
- 6.14.5 GenSci Recent Developments
- 6.15 Gedeon Richter
- 6.15.1 Gedeon Richter Company Information
- 6.15.2 Gedeon Richter Business Overview
- 6.15.3 Gedeon Richter Urotropin for Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.15.4 Gedeon Richter Urotropin for Injection Product Portfolio
- 6.15.5 Gedeon Richter Recent Developments
7 North America by Country
- 7.1 North America Urotropin for Injection Sales by Country
- 7.1.1 North America Urotropin for Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Urotropin for Injection Sales by Country (2021-2026)
- 7.1.3 North America Urotropin for Injection Sales Forecast by Country (2027-2032)
- 7.2 North America Urotropin for Injection Market Size by Country
- 7.2.1 North America Urotropin for Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Urotropin for Injection Market Size by Country (2021-2026)
- 7.2.3 North America Urotropin for Injection Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Urotropin for Injection Sales by Country
- 8.1.1 Europe Urotropin for Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Urotropin for Injection Sales by Country (2021-2026)
- 8.1.3 Europe Urotropin for Injection Sales Forecast by Country (2027-2032)
- 8.2 Europe Urotropin for Injection Market Size by Country
- 8.2.1 Europe Urotropin for Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Urotropin for Injection Market Size by Country (2021-2026)
- 8.2.3 Europe Urotropin for Injection Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Urotropin for Injection Sales by Country
- 9.1.1 Asia-Pacific Urotropin for Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Urotropin for Injection Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Urotropin for Injection Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Urotropin for Injection Market Size by Country
- 9.2.1 Asia-Pacific Urotropin for Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Urotropin for Injection Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Urotropin for Injection Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Urotropin for Injection Sales by Country
- 10.1.1 South America Urotropin for Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Urotropin for Injection Sales by Country (2021-2026)
- 10.1.3 South America Urotropin for Injection Sales Forecast by Country (2027-2032)
- 10.2 South America Urotropin for Injection Market Size by Country
- 10.2.1 South America Urotropin for Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Urotropin for Injection Market Size by Country (2021-2026)
- 10.2.3 South America Urotropin for Injection Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Urotropin for Injection Sales by Country
- 11.1.1 Middle East and Africa Urotropin for Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Urotropin for Injection Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Urotropin for Injection Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Urotropin for Injection Market Size by Country
- 11.2.1 Middle East and Africa Urotropin for Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Urotropin for Injection Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Urotropin for Injection Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Urotropin for Injection Value Chain Analysis
- 12.1.1 Urotropin for Injection Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Urotropin for Injection Production Mode & Process
- 12.2 Urotropin for Injection Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Urotropin for Injection Distributors
- 12.2.3 Urotropin for Injection Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst